Immediate Impact
1 from Science/Nature 21 hit
Citing Papers
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
2023 Hit
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
2023 Hit
Works of Fumito Tsuji being referenced
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
2017 Hit